Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational, Cross-sectional Study to Analyze the Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete Remission, Partial Remission or Stabilization of Disease During More Than 3 Years

NCT01433926 is registered in ClinicalTrials.gov with Asociación para el Progreso de la Oncología en Málaga as lead sponsor.

NCT NCT01433926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01433926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational, Cross-sectional Study to Analyze the Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete Remission, Partial Remission or Stabilization of Disease During More Than 3 Years
Lead sponsor
Asociación para el Progreso de la Oncología en Málaga
Phase
Observational
Overall status
Completed
Start date
September 30, 2009
Completion date
September 30, 2011
Enrollment
114 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

her-2 positive breast cancer